142643-29-6

Basic information

• Product Name: 3-N-Boc-Aminomethylpiperidine
• Synonyms: 3-N-BOC-AMINOMETHYL PIPERIDINE;3-AMINOPIPERIDINE, 3-BOC PROTECTED;(3-AMINOMETHYL, N-BOC PROTECTED)PIPERIDINE;(+/-)-3-(BOC-AMINOMETHYL)PIPERIDINE;3-BOC-AMINOMETHYL PIPERIDINE;3-BOC-AMINOPIPERIDINE;CARBAMIC ACID, 3-PIPERIDINYL-, 1,1-DIMETHYLETHYL ESTER;TERT-BUTYL (PIPERIDIN-3-YLMETHYL) CARBAMATE
• CAS NO: 142643-29-6
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: pharmacetical;Amines;Pyrans, Piperidines &Piperazines;Piperidine;API intermediates;Pyrans, Piperidines & Piperazines
• Mol File: 142643-29-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 60-70 °C(lit.)
• Boiling Point: 321.8 °C at 760 mmHg
• Flash Point: 148.4 °C
• Appearance: Off-white solid
• Density: 0.981
• Vapor Pressure: 0.00029mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 12.71±0.46(Predicted)
• BRN: 7023643
• CAS DataBase Reference: 3-N-Boc-Aminomethylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-N-Boc-Aminomethylpiperidine(142643-29-6)
• EPA Substance Registry System: 3-N-Boc-Aminomethylpiperidine(142643-29-6)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3259 8/PG 2
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 142643-29-6(Hazardous Substances Data)

Usage

Description

3-N-Boc-Aminomethylpiperidine is a white powder chemical compound that serves as a reagent in the preparation of various pharmaceutical compounds, particularly in the synthesis of Tylophorine analogs. It is utilized in enzymatic acylation processes, which are crucial for the development of novel drugs with potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
3-N-Boc-Aminomethylpiperidine is used as a reagent for the preparation of Tylophorine analogs, which are compounds with potential therapeutic applications. Its role in enzymatic acylation processes is essential for the synthesis of these analogs, contributing to the development of new drugs.
Used in Research and Development:
In the field of research and development, 3-N-Boc-Aminomethylpiperidine is used as a reagent for the preparation of 9-substituted phenanthrene-based Tylophorine analogs. These analogs are being studied for their potential applications in various therapeutic areas, including the treatment of various diseases and conditions.
Used in Enzymatic Acylation:
3-N-Boc-Aminomethylpiperidine is also used in enzymatic acylation, a process that involves the transfer of an acyl group from an acyl donor to an acceptor molecule. This process is crucial in the synthesis of various pharmaceutical compounds and can lead to the development of novel drugs with improved efficacy and safety profiles.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-8-9-5-4-6-12-7-9/h9,12H,4-8H2,1-3H3,(H,13,14)/p+1/t9-/m0/s1

Upstream product

• 102297-41-6 3-<amino>methyl>pyridine 
• 3731-52-0 3-Aminomethylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 220031-84-5 3-[(tert-butoxycarbonylamino)methyl]-piperidin-1-ylcarboxylic acid benzyl ester 
• 220031-61-8 tert-butyl (1-benzylpiperidin-3-yl)methylcarbamate 
• 4138-26-5 nipecotamide 
• 1378312-69-6 (±)-1-benzoylpiperidine-3-carboxamide 
• 124257-62-1 (±)-(1-benzylpiperidin-3-yl)methanamine 

Downstream Products

• 861390-37-6 [1'-(3,4-dichloro-benzyl)-4'-methyl-[1,4']bipiperidinyl-3-ylmethyl]-carbamic acid tert-butyl ester 
• 852358-83-9 tert-butyl [1-(6-oxo-6-phenylhexyl)piperidin-3-ylmethyl]carbamate 
• 791817-74-8 (1-benzenesulfonyl-piperidin-3-ylmethyl)-carbamic acid tert-butyl ester 
• 642443-59-2 C₂₀H₂₉ClN₂O₃ 
• 879275-33-9 (R)-1-piperidin-3-ylmethyl-carbamic acid tert-butyl ester 
• 1220669-82-8 octanoyl-Tyr(Bzl)-Leu-Pro-(3-aminomethylpiperidine) trifluoroacetate 
• 1232059-85-6 C₁₇H₂₆N₂O₂ 
• 1232059-89-0 C₁₈H₂₄ClN₃O₂ 
• 1260001-12-4 C₃₉H₅₃N₅O₅ 
• 1336908-46-3 4-(4-fluorophenoxy)pyridine-2-carboxylic acid (1-isopropylpiperidin-3-ylmethyl)amide 
• 1336908-47-4 4-(4-fluorophenoxy)pyridine-2-carboxylic acid ((S)-1-isopropylpiperidin-3-ylmethyl)amide 
• 1336908-48-5 4-(4-fluorophenoxy)pyridine-2-carboxylic acid ((R)-1-isopropylpiperidin-3-ylmethyl)amide 
• 1336908-50-9 4-benzyloxypyridine-2-carboxylic acid (1-isopropylpiperidine-3-ylmethyl)-amide 
• 1336908-52-1 4-phenoxypyridine-2-carboxylic acid (1-isopropylpiperidin-3-ylmethyl)amide 

Relevant articles and documents

Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents

Tremendous efforts have been dedicated to the development of effective therapeutics against Alzheimer's disease, which represents the most common debilitating neurodegenerative disease. Multifunctional agents are molecules designed to have simultaneous effects on different pathological processes. Such compounds represent an emerging strategy for the development of effective treatments against Alzheimer's disease. Here, we report on the synthesis and biological evaluation of a series of nitroxoline-based analogs that were designed by merging the scaffold of 8-hydroxyquinoline with that of a known selective butyrylcholinesterase inhibitor that has promising anti-Alzheimer properties. Most strikingly, compound 8g inhibits self-induced aggregation of the amyloid beta peptide (Aβ1-42), inhibits with sub-micromolar potency butyrylcholinesterase (IC50 = 215 nM), and also selectively complexes Cu2+. Our study thus designates this compound as a promising multifunctional agent for therapeutic treatment of Alzheimer's disease. The crystal structure of human butyrylcholinesterase in complex with compound 8g is also solved, which suggests ways to further optimize compounds featuring the 8-hydroxyquinoline scaffold.

N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents

In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased. While BChE is a viable therapeutic target for alleviation of symptoms caused by cholinergic hypofunction, MAO-B is a potential therapeutic target for prevention of neurodegeneration in Alzheimer's disease. Starting with piperidine-based selective human (h)BChE inhibitors and propargylamine-based MAO inhibitors, we have designed, synthesized and biochemically evaluated a series of N-propargylpiperidines. All of these compounds inhibited hBChE with good selectivity over the related enzyme, acetylcholinesterase, and crossed the blood-brain barrier in a parallel artificial membrane permeation assay. The crystal structure of one of the inhibitors (compound 3) in complex with hBChE revealed its binding mode. Three compounds (4, 5, 6) showed concomitant inhibition of MAO-B. Additionally, the most potent hBChE inhibitor 7 and dual BChE and MAO-B inhibitor 6 were non-cytotoxic and protected neuronal SH-SY5Y cells from toxic amyloid β-peptide species.

QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS

The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.